Pharmafile Logo
Pharmafocus logo
Advanced Search

Imfinzi

Showing 15 posts of 24 posts found.

astrazeneca_plaque

AstraZeneca to withdraw Imfinzi US indication for bladder cancer

February 22, 2021
Sales and Marketing AstraZeneca, Imfinzi

AstraZeneca will voluntarily withdraw the Imfinzi (durvalumab) indication in the US for previously treated adult patients with locally advanced or …

News
astrazeneca_sign_sky

AstraZeneca’s Imfinzi gets EU and UK approval for new dosing option

January 15, 2021
Medical Communications AstraZeneca, Cancer, Imfinzi

AstraZeneca’s Imfinzi (durvalumab) has been approved in the EU and the UK for an additional dosing option in locally advanced, …

News
astrazeneca_building_white

EMA panel recommends label extension of AstraZeneca’s Imfinzi in non-small cell lung cancer

December 15, 2020
Manufacturing and Production, Sales and Marketing AstraZeneca, Europe, Imfinzi, NSCLC

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has backed a new dosing regimen of AstraZeneca’s …

News

AstraZeneca scores Japanese approval for Imfinzi combo in extensive-stage small cell lung cancer

August 21, 2020
Medical Communications, Sales and Marketing AstraZeneca, Imfinzi, Japan

AstraZeneca’s Imfinzi (durvalumab) has secured approval in Japan for the treatment of extensive-stage small cell lung cancer when combined with etoposide and …

News
astrazeneca_sign_sky

Two CHMP recommendations for AstraZeneca: Imfinzi in first-line lung cancer, Calquence in chronic lymphocytic leukaemia

July 27, 2020
Sales and Marketing AstraZeneca, CHMP, Calquence, EMA, Imfinzi

AstraZeneca has secured two new recommendations for approval of its products from the European Medicines Agency’s Committee for Medicinal Products …

News
astrazeneca_building_white

FDA immunotherapy first with the approval of AZ’s Imfinzi in first-line extensive-stage small cell lung cancer

March 30, 2020
Sales and Marketing AstraZeneca, Cancer, FDA, Imfinzi, lung cancer, pharma

AstraZeneca has seized FDA approval for its immune checkpoint inhibitor Imfinzi (durvalumab) in the first-line treatment of extensive-stage small cell …

News
astrazeneca_building_white

Success and failure at Phase 3 for AstraZeneca’s Imfinzi combos in first-line small cell lung cancer

March 17, 2020
Manufacturing and Production, Research and Development AstraZeneca, Cancer, Imfinzi, pharma

AstraZeneca has pulled back the curtain on new Phase 3 data for Imfinzi (durvalumab) in the first-line treatment of extensive-stage …

News
az_logo

Phase 3 failure for AstraZeneca’s Imfinzi combo in unresectable metastatic bladder cancer

March 6, 2020
Medical Communications, Research and Development AstraZeneca, Cancer, Imfinzi, bladder cancer, pharma, trial failure

New Phase 3 has been released by AstraZeneca, showing that the PD-L1 inhibitor Imfinzi (durvalumab), when combined with tremelimumab, failed …

News
china-1081714_1920

China approves AstraZeneca’s Imfinzi for advanced non-small cell lung cancer

December 12, 2019
Sales and Marketing AstraZeneca, Imfinzi, pharma

AstraZeneca’s Imfinzi (durvalumab) is set to be made available in China after the country’s National Medical Products Administration (NMPA) decided …

News

FDA gives priority review for AstraZeneca’s Imfinzi

November 29, 2019
Medical Communications AstraZeneca, Cancer, FDA, Imfinzi, lung cancer

The FDA has granted a priority review of AstraZeneca’s cancer treatment drug Imfinzi (durvalumab) for treatment of patients with untreated …

News

AstraZeneca’s Imfinzi triple combo beats chemo in treatment-naive metastatic lung cancer

October 29, 2019
Manufacturing and Production, Research and Development AstraZeneca, Cancer, Imfinzi, NSCLC, lung cancer, pharma

AstraZeneca has unveiled positive new Phase 3 data for the combination of Imfinzi (durvalumab) and anti-CTLA4 antibody tremelimumab with chemotherapy …

News

AstraZeneca’s Imfinzi combo tops chemotherapy in treatment-naive advanced lung cancer

September 9, 2019
Sales and Marketing AstraZeneca, Cancer, Imfinzi, lung cancer, pharma

AstraZeneca has unveiled new Phase 3 data for its immunotherapy Imfinzi (durvalumab), showing that it achieved its primary endpoint when …

News
astrazeneca_building_white

AstraZeneca’s Imfinzi flops in advanced treatment-naive non-small cell lung cancer

August 21, 2019
Research and Development AstraZeneca, Cancer, Imfinzi, lung cancer, pharma

New data have emerged illustrating that AstraZeneca’s anti-CTLA4 antibody Imfinzi (durvalumab) failed to meet its primary endpoint when used in …

News
astrazeneca_plaque

AstraZeneca’s Imfinzi gets orphan drug designation from FDA

July 12, 2019
Medical Communications AstraZeneca, Cancer, Imfinzi, lung cancer, pharma

AstraZeneca’s cancer immunotherapy Imfinzi has been granted orphan drug status as a treatment for small cell lung cancer (SCLC). The …

News
astrazeneca-sign

AstraZeneca’s Imfinzi meets endpoint at Phase 3 interim analysis in extensive-stage small cell lung cancer

June 27, 2019
Research and Development AstraZeneca, Imfinzi, pharma

AstraZeneca has lifted the curtain on new Phase 3 data for Imfinzi (durvalumab) in the first-line treatment of extensive-stage small …

News

Latest content

Novo Nordisk partners with UNICEF to prevent global childhood obesity

September 21, 2023

EC approves Menarini Group’s Orserdu for breast cancer treatment

September 21, 2023

Pharmanovia acquires CNS portfolio from Sanofi

September 20, 2023

Exscientia enters AI drug discovery collaboration with Merck KGaA

September 20, 2023

EC approves Pfizer’s Litfulo for adolescents and adults with alopecia

September 19, 2023